

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Darolutamide with androgen deprivation therapy for
treating non-metastatic hormone-relapsed prostate cancer**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

(when no ACD was issued)

- | |
|-------------------------------------------------------------------------------------------------------------------------------|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|-------------------------------------------------------------------------------------------------------------------------------|

The comments on access to treatments varying by geographical region was noted by committee. This was not considered to be an equality issue.

- | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

It was noted that older men may be less likely to be able to tolerate the cytotoxic chemotherapy than younger men. Because docetaxel is not used for non-metastatic hormone-relapsed prostate cancer this was not considered to be an equality issue.

- | |
|----------------------------------------------------------------------------------------------------------------------------------|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|----------------------------------------------------------------------------------------------------------------------------------|

No.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No. Darolutamide is an oral treatment and no barriers to or difficulties with access are anticipated.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

No, because none of the issues raised were considered to be equality issues.

Approved by Associate Director (name): Nicole Elliott

Date: 28/09/2020